<DOC>
	<DOCNO>NCT02573844</DOCNO>
	<brief_summary>The purpose study determine whether Proklama effective significative reduction pain , symptoms IBS 's related , improve quality life concern IBS disease .</brief_summary>
	<brief_title>Pain Relief In Irritable Bowel Syndrome</brief_title>
	<detailed_description>This phase IV , double- blind , randomize , placebo control , moncentric study . Males woman 18 y.o . Irritable bowel syndrome ( IBS ) diagnose apply Rome III criterion enrol consecutively . The study consist 4 period : - A screening 's period 2 week start visit 1 , useful screen potentially eligible patient perform diagnostic investigation necessary confirm disgnosis . - A run- 's period , start visit 2 last 2 week represent baseline without specific treatment order characterize severity symptomatology evaluate patient ' compliance relative daily diary - A 2 weeks- treatment 's period ( active/ placebo ) start visit 3 . The 1st day period treatment , eligible patient randomize follow 1:1 ratio receive Proklama ( 1 sachet/ day ) placebo . Treatments administred daily whole 2 weeks- treatment 's period . - A wash 's period last 2 week start visit 4 , perform day end 2 weeks- treatment 's period . - A 2 weeks- treatment 's period ( placebo/ active ) start visit 5 , perform last day wash 's period . During visit patient receive second treatment , follow crossover design .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1. patient 18 y.o . 2. clinical diagnosis IBS follow Rome III symptom base criterion : 1. abdominal pain discomfort recur least 3 day month previous 3 month , associate 2 follow characteristic least : improved evacuation ; onset associate variation stool frequency ; onset associate change stool consistency 2. onset symptomatology least 6 month precede diagnosis 3. additional criterion : mean severity abdominal pain high 3 11points NRS 3 . For patient 50 y.o . positive familiarity colorectal cancer : normal colonoscopy perform within 5 year begin screen 's period symptomatology 's onset 4 . For patient 65 y.o . : absence ischemic / microscopic colitis , organic gastrointestinal disorder , highlight colonoscopy biopsy perform within 6 month begin screen 's period 5 . For fertile sexually active woman : use effective contraception failure rate le 1 % one year trial period 30 day end . Oral contraceptive admit long formulation n't undergo change 6 month preceeding trial . 6 . Physical examination negative period screen 7 . Absence significant alteration 12 lead ECG period screen . 8 . Normal haematochemical parameter period screen 9 . Compliant patient towards procedure provide study , expecially use daily diary 10 . Patients mental integrity , able express inform pocedure relate protocol , compliant toward clinical examination provide protocol . 11 . Patients willing avoid loperamide laxatives use 3 day precede run whole run 's period ( verified randomization ) 12 . Patients 2 run 's week report average daily intensity abdominal pain every week &gt; 3 010 ( NRS ) 1 . Male gender 2 . Patient diagnosis IBS subtype constipation , mixed IBS , unsubtyped IBS accord Rome III criteria 3 . Patient surgery meet follow criterion : ) colonic major abdominal surgery , i.e . bariatric surgery stomach , small/ large bowel large vessel abdominal surgery ( except appendicectomy , hysterectomy , cholecystectomy , caesarean section , laparoscopic surgery ) . 4 . Patient elective major surgery plan expect time study . 5 . Patient history inflammation bowel disease , complicate diverticulosis ( i.e . diverticulitis ) , ischaemic colitis , microscopic colitis . 6 . Patient history organic abnormality GI tract , intestinal obstruction , stricture , toxic megacolon , GI perforation , fecal impaction , gastric banding , adhesion impair intestinal circulation ( e.g. , aortoiliac disease ) . 7 . Patient history pancreatitis etiology , cholecystitis symptomatic gallbladder stone disease previous 6 month . 8 . Patoent active biliary duct disease history Sphincter Oddi dysfunction . 9 . Patient history gluten enteropathy . 10 . Patient history lacotse intolerance assess response diet . 11 . Patient current previous diagnosis neoplasia ( except nonGI ) neoplasia complete remission &lt; = 5 year , squamous basal cell carcinomas cervical carcinoma situ ) . 12 . Patient history ectopic endometriosis . 13 . Patient history positive test ova parasite , clostridium difficile toxin occult blood stool previous 6 month . 14 . Patient history human immunodeficiency virus infection . 15. patient history cardiovascular event , include stroke , myocardial infarction , congestive heart failure ( NYHA class &gt; 2 ) , transient ischemic attack previous 6 month . 16 . Patient uncontrolled hypertension , define systolic blood pressure &lt; 180 mmHg diastolic blood pressure &lt; 100 mmHg . 17 . Patient insulin dependent diabetes mellitus . 18 . Patient major phychiatric neurological disorder . 19 . Patient unstable medical condition may compromise efficacy safety assessment require study and/or require change concomitant medication . 20 . Patient history abnormal thyroid function . Patient candidate study thyroid hormone replacement therapy stable least 2 month . 21 . Patient evidence clinically hepatic disease define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time rthe upper limit normal total bilirubin &gt; 3 mg/dl ( &gt; 51.3 mmoL/L ) , exception Gilbert 's syndrome albumin &lt; 2.8 g/dL Screening period . 22 . Patient sever renal insufficiency ( Glomerular Filtration Rate [ GFR ] &lt; 30 mL/min/ 1.73 m^2 calculate Cockcroft . Gault formula adjust body surface area [ BSA ] ) Screening period 23 . Patient evidence anemia confirm hemoglobin &lt; 9 g/dL Screening period . 24 . Relevant change dietary habit , lifestyle exercise regimen maintain duration study . 25 . Use prohibit concurrent medication within previous month , namely : Antibiotics ( 4 month case rifaximin ) ; 5 HT3 antagonist alosetron . 26 . Use prohibit concurrent medication previous 7 day namely : Antimuscarinic drug ; Drug enhance GI motility prokinetic agent stimulant GI contractility drug , laxative , anti diarrhoeal agent ( except loperamide , please refer inclusion criterion No.12 ) ; Anaglesic drug ( opioids non steroidal anti inflammatory drug ) . NOTE : short term use paracetamol allow max 2 consecutive day ; Fibre product herbal preparation ; Antidepressants . NOTE : use single antidepressant allow drug type dose regimen change previous 6 month ; Benzodiazepinews . NOTE : use single bendodiazepine allow administered sleep inducer drug type dose regimen change previous 6 month . 27 . Pregnancy breastfeed . 28 . Hypersensitivity drug excipients . 29 . Patient able understand collaborate throughout study . 30 . Patient unable swallow solid , oral dosage form whole aid liquid ( patient may chew , divide , dissolve , crush study drug ) . 31 . Partecipation clinical study previous 4 week patient currently enrol clinical study another investigational drug . 32 . Patient condition , opinion Investigator , would compromise well patient requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>abdominal pain</keyword>
	<keyword>rome III criterion</keyword>
	<keyword>abdominal distension</keyword>
	<keyword>consistency stool</keyword>
	<keyword>stool frequency</keyword>
	<keyword>meteorism</keyword>
	<keyword>flatulence</keyword>
	<keyword>abdominal discomfort</keyword>
	<keyword>proklama</keyword>
	<keyword>probiotic</keyword>
	<keyword>alga klamath</keyword>
	<keyword>aphanizomenon flos-aquae</keyword>
	<keyword>prebiotics</keyword>
	<keyword>colitis ulcerosa</keyword>
</DOC>